CORVUS PHARMACEUTICALS,INC. (NASDAQ:CRVS) Files An 8-K Other EventsItem 8.01 Other Events.
On February 14, 2017, Vernalis plc (“Vernalis”) issued a press release announcing the achievement of a clinical milestone under the License Agreement, dated February 25, 2015, by and between Corvus Pharmaceuticals, Inc. and Vernalis (R&D) Limited, as amended, which triggered a milestone payment of $3 million to Vernalis made on February 13, 2017.
About CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS)
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue. CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) Recent Trading Information
CORVUS PHARMACEUTICALS, INC. (NASDAQ:CRVS) closed its last trading session up +0.06 at 13.90 with 103,495 shares trading hands.
